[Click e-Stock] "Syntekabio Expected to Achieve Earnings Growth Driven by AI Drug Discovery Platform"
On March 16, Eugene Investment & Securities analyzed that Syntekabio is expected to enter a phase of earnings growth, driven by the expansion of its AI drug discovery platform business.
Jongseon Park, a researcher at Eugene Investment & Securities, stated, "The essence of the AI drug discovery market is competition in efficiency," adding, "If a company secures the technology to quickly identify effective candidate compounds with fewer experiments, it can generate high added value."
According to the report, the global new drug development value chain typically consists of the following stages: Discovery, Pre-clinical, Clinical, CDMO (Contract Development and Manufacturing Organization), and Commercialization. Recently, technological capabilities and data-driven research at the Discovery stage have emerged as key competitive strengths in the global market.
Notably, China is rapidly growing in the drug discovery sector, expanding its presence in the global market, and the size of its drug candidate discovery service market is estimated to be about 17 times larger than that of Korea.
Researcher Park explained that an integrated technological base combining AI-driven design, data infrastructure, and experimental validation systems is a core component of competitive power in AI drug discovery.
Amid this trend, the report noted that Syntekabio is actively expanding its AI drug discovery platform business by scaling up its AI Driven Asset Program, which identifies candidate compounds using data center-level AI infrastructure, conducts large-scale experimental validation, and then pursues technology transfer.
Additionally, Syntekabio is proactively identifying promising targets through its proprietary AI platforms, Sm-ARS (for small molecules) and Ab-ARS (for antibodies), and is building a business model that links AI-driven candidate discovery to pipeline expansion by leveraging a global CRO infrastructure for experimental validation.
In terms of performance, growth is evident. According to the report, Syntekabio's provisional consolidated results for the fourth quarter of last year recorded sales of 1.8 billion won and an operating loss of 2.5 billion won. Compared to the same period the previous year, sales increased by 1,453.9%, while operating loss decreased by 31.2%. The surge in sales was attributed to a 1,349.6% year-on-year increase in AI drug discovery platform sales.
The provisional annual results for last year showed sales of 3.4 billion won and an operating loss of 10.7 billion won, representing a 2,736.7% increase in sales from the previous year. Although the operating loss continued, it decreased by 24.8%. Park explained, "Revenue growth was driven by increased AI drug discovery platform sales, as well as diversification into data center services and SI services."
It is especially anticipated that the scale of earnings improvement will expand further in 2026. Park projected, "Annual sales in 2026 are expected to reach 7.7 billion won, a 125% increase from the previous year, while operating loss is expected to decrease by about 80%." He added, "With continued expansion of the AI drug discovery platform business and diversification, revenue growth is expected to be sustained, and profitability will see significant improvement."
He also noted, "A reduction in accounting expenses such as depreciation, amortization of intangible assets, and stock compensation costs, along with cost-saving efforts including downsizing the U.S. branch and marketing organization and restructuring inefficient personnel, will also contribute to improved profitability."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, Syntekabio is focusing on enhancing pipeline value by expanding its AI Driven Asset Program, which proactively discovers candidate compounds based on its AI drug discovery platform. If achievements in candidate validation and technology transfer become visible in the future, this is expected to drive further earnings growth and an increase in corporate value.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.